CD19xBCMAxCD3
-
>$600M! Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Congratulations! This is the latest successful case of NewCo for China pharma and biotech companies
-
超6亿美元！维立志博与Aditum Bio合作成立Oblenio Bio，全力推进自免领域三特异性T细胞衔接器研发
热烈祝贺！NewCo模式的最新成功案例
